Top-Rated StocksTop-RatedNASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $23.33 -1.11 (-4.54%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$22.64▼$24.7550-Day Range$18.93▼$25.6952-Week Range$4.22▼$26.12Volume592,570 shsAverage Volume917,924 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nurix Therapeutics alerts: Email Address Nurix Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside15.7% Upside$27.00 Price TargetShort InterestBearish18.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 11 Articles This WeekInsider TradingSelling Shares$1.45 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.95) to ($2.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.46 out of 5 starsMedical Sector667th out of 910 stocksPharmaceutical Preparations Industry308th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNurix Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted18.80% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 0.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRIX. Previous Next 1.9 News and Social Media Coverage News SentimentNurix Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Nurix Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,449,070.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Nurix Therapeutics is held by insiders.Read more about Nurix Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nurix Therapeutics are expected to grow in the coming year, from ($2.95) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -7.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -7.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Nurix Therapeutics Stock (NASDAQ:NRIX)Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Read More NRIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRIX Stock News HeadlinesSeptember 5 at 5:07 AM | insidertrades.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Christine Ring Sells 9,050 SharesAugust 27, 2024 | insidertrades.comChristine Ring Sells 9,870 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) StockSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 6 at 7:00 AM | globenewswire.comNurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering SummitSeptember 6 at 4:08 AM | americanbankingnews.comOppenheimer Increases Nurix Therapeutics (NASDAQ:NRIX) Price Target to $30.00September 5 at 9:58 PM | benzinga.comNurix Therapeutics (NASDAQ:NRIX) Stock, Short Interest ReportSeptember 5 at 9:58 PM | msn.comNurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right NowAugust 29, 2024 | globenewswire.comNurix Therapeutics to Participate in Upcoming Investor ConferencesSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 29, 2024 | americanbankingnews.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $246,848.70 in StockAugust 29, 2024 | lse.co.ukNurix Therapeutics Share Price (NRIX.US)August 28, 2024 | americanbankingnews.comHoute Hans Van Sells 20,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) StockAugust 28, 2024 | finance.yahoo.comNRIX Sep 2024 22.500 put (NRIX240920P00022500)August 27, 2024 | finance.yahoo.comInsider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)August 14, 2024 | ca.finance.yahoo.comNRIX Sep 2024 25.000 callAugust 14, 2024 | ca.finance.yahoo.comNRIX Aug 2024 22.500 putAugust 13, 2024 | ca.finance.yahoo.comNRIX Aug 2024 30.000 callAugust 13, 2024 | ca.finance.yahoo.comNRIX Jan 2025 30.000 callSee More Headlines Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/11/2024Today9/07/2024Next Earnings (Estimated)10/10/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRIX CUSIPN/A CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$36.00 Low Stock Price Target$10.00 Potential Upside/Downside+15.7%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,950,000.00 Net Margins-264.84% Pretax Margin-264.55% Return on Equity-67.78% Return on Assets-44.37% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$62.30 million Price / Sales18.41 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book5.65Miscellaneous Outstanding Shares49,151,000Free Float45,612,000Market Cap$1.15 billion OptionableOptionable Beta2.23 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Arthur T. Sands M.D. (Age 62)Ph.D., CEO, President & Director Comp: $986.32kMr. Johannes Van Houte (Age 58)Chief Financial Officer Comp: $681.98kDr. Gwenn M. Hansen Ph.D. (Age 53)Chief Scientific Officer Comp: $702.75kDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardMr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardDr. Arthur Weiss M.D.Ph.D., Founder & Member of Scientific Advisory BoardRita KwongSenior Accounting ManagerDr. Christine Ring J.D. (Age 59)Ph.D., Chief Legal Officer, Secretary & Chief Compliance Officer Comp: $595.83kMr. Eric C. Schlezinger J.D. (Age 57)Chief People Officer Dr. Jason Kantor Ph.D.Chief Business OfficerMore ExecutivesKey CompetitorsPraxis Precision MedicinesNASDAQ:PRAXArvinasNASDAQ:ARVNLigand PharmaceuticalsNASDAQ:LGNDCOMPASS PathwaysNASDAQ:CMPSAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsChristine RingSold 9,050 sharesTotal: $225,707.00 ($24.94/share)Houte Hans VanSold 20,000 sharesTotal: $504,400.00 ($25.22/share)Teachers Retirement System of The State of KentuckyBought 27,695 shares on 8/26/2024Ownership: 0.056%Christine RingSold 9,870 sharesTotal: $246,848.70 ($25.01/share)Driehaus Capital Management LLCBought 1,283,108 shares on 8/16/2024Ownership: 2.611%View All Insider TransactionsView All Institutional Transactions NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $10.32 at the beginning of the year. Since then, NRIX stock has increased by 126.1% and is now trading at $23.33. View the best growth stocks for 2024 here. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) posted its quarterly earnings data on Thursday, July, 11th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.08. The business had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative trailing twelve-month return on equity of 67.78% and a negative net margin of 264.84%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional investors of Nurix Therapeutics include ARK Investment Management LLC (3.61%), Driehaus Capital Management LLC (2.61%), Candriam S.C.A. (2.37%) and Affinity Asset Advisors LLC (1.86%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND) and Delta Air Lines (DAL). This page (NASDAQ:NRIX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
